Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Feature|Articles|March 12, 2026
Elucidating Treatment Selection for Metastatic HSPC at ASCO GU 2026
Author(s)Roman Fabbricatore
Fact checked by: Russ Conroy, Justin Mancini
By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.
Advertisement
Advertisement
In an oral session at the
Related to this article
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Advertisement
Advertisement